Not provided
Not provided
Not provided
Not provided
Lack of clinician interest and insufficient patient availability
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Regionshospital Nordjylland | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
This clinical investigation will be carried out as a randomized controlled trial conducted at the Northern Regional Hospital, Hjørring. This investigation will enrol 36 patients suffering from severe knee osteoarthritis pain, primarily from the orthopaedic ward at Hjørring Hospital, where potential participants will be identified during routine consultations.
The RELEARN intervention consists of encephalography (EEG) neurofeedback of cerebral movement evoked signatures of pain, where the participants will be instructed in attempting to manipulate these signatures to reduce pain perception. This investigation is carried out to analyse the clinical performance and safety of the RELEARN neurofeedback software.
The participants will be randomized into treatment group A and control group B, 1:1 and be stratified based on age, sex, and ethnicity. Group A participants will be asked to attend eight sessions of RELEARN neurofeedback with an approximate duration of 45 minutes per session, and group B participants will be asked to attend eight sessions with no intervention and serve as no-treatment controls with an approximate duration of 5 minutes per session. Both groups (A and B) will undergo three follow-up sessions: one month, three months, and five months post intervention.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RELEARN - Intervention | Experimental | Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. In addition, intervention group participants will be asked to attend eight sessions of RELEARN neurofeedback with an approximate duration of 45 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention |
|
| Standard care control | Active Comparator | Standard Care control. Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RELEARN Neurofeedback | Device | Standard care + The RELEARN intervention. Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, intervention group participants will be subject to the RELEARN intervention, consisting of encephalography (EEG) neurofeedback of cerebral movement evoked signatures of pain, where the participants will be instructed in attempting to manipulate these signatures to reduce pain perception. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Pain Perception | Change in the 10-point Visual Analogue Scale (VAS) over time (0 = no pain, 10 = maximum imaginable pain) | Up to 6 month |
| Measure | Description | Time Frame |
|---|---|---|
| Change in quality of life | QoL (EQ-5D), Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status). | Up to 6 month |
| Change in pain characteristics |
Not provided
Inclusion Criteria:
Age 18-65 years old
Knee arthrosis (Kellgren-Lawrence score of ≥ 2)
24h VAS ≥ 4
Ongoing pain, lasting more than three months
Exclusion Criteria:
Participants who meet any of the below criteria will be excluded from the investigation:
Pregnant or lactating woman
Use of opioids or cannabis
Active drug addiction defined as the use of cannabis, opioids, or other drugs
Previous or current neurologic, systemic, or mental illness, including any liver, kidney or metabolic disease.
Rheumatoid arthritis
Evidence of other pain types such as visceral, neuropathic, or malignant pain.
Evidence of other sources of ongoing pain such as root affect, traumas, or congenital malformation
Severe inflammation in the area of interest
Blindness or deafness
Consumption of alcohol, caffeine, nicotine on test day
Recent history of fractures or surgery in the area of interest
Participation in other clinical trials throughout the study period and one month prior to participation
History of epilepsy
Obesity class III and above. I.e. BMI > 39,9
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Peter Christian Leutscher, Dr. PhD | Center of Clinical Research, Regional Hospital North Jutland, Hjørring, Denmark | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Clinical Research | Hjørring | 9800 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D059350 | Chronic Pain |
| D010003 | Osteoarthritis |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Randomised controlled study
Not provided
Not provided
Not provided
Not provided
|
| Standard care control | Other | Standard Care control. Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention |
|
Pain characteristics (MPQ and WOMAC) |
| Up to 6 month |
| Change in consumption of analgesics | Consumption of analgesics (MQS-III) | Up to 6 month |
| Evaluate the safety of the RELEARN software by assessment of adverse events and device deficiencies | Incidence of AE/ADE/SAE/SADE/DD | Up to 6 month |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |